In a Bayesian adaptive randomized trial comparing various metronomic chemotherapy regimens versus conventional chemotherapy plus anti-PD-1 in women with HER2-negative breast cancer, a metronomic chemotherapy-based regimen appears to be clinically effective, with evidence that on-treatment immune changes may be trackable for assessing response.
- Hongnan Mo
- Yongpei Yu
- Fei Ma
